BioMarin Receives FDA Approval for Palynziq Use in Adolescents

Why It Matters

The approval gives PKU adolescents a diet‑independent therapy, improving quality of life and expanding BioMarin’s market reach. It also positions the company for European growth and strengthens its strategic pipeline.

Key Takeaways

• FDA approves Palynziq for adolescents 12+ with PKU
• 44.4% achieved target phenylalanine levels in trial
• Mean phenylalanine drop 828 µmol/L, 94% reduction
• Intact protein intake rose 318%, medical‑food fell 55%
• Common adverse reactions: arthralgia, dizziness, fatigue, nausea

Pulse Analysis

Phenylketonuria, a rare inherited metabolic disorder, has long been managed through strict low‑phenylalanine diets and medical‑food formulas. While effective at preventing neurotoxicity, dietary adherence is burdensome, especially for adolescents navigating social settings. Palynziq (pegvaliase‑pqpz) offers a novel enzyme substitution approach, breaking down phenylalanine in the bloodstream and directly addressing the biochemical root cause. This therapeutic shift reflects a broader industry trend toward disease‑modifying treatments that reduce reliance on lifestyle constraints.

The FDA’s clearance stems from the PEGASUS Phase III trial, which demonstrated that nearly half of the adolescent cohort achieved phenylalanine concentrations within recommended limits, with a striking 94% average reduction from baseline. Beyond biochemical markers, participants reported a 318% surge in intact protein consumption and a 55% decline in medical‑food usage, indicating a meaningful relaxation of dietary restrictions. Adverse events were largely confined to the induction phase, featuring arthralgia, dizziness, fatigue and nausea, and tapered during maintenance, suggesting manageable safety profiles for long‑term therapy.

From a commercial perspective, the approval unlocks a sizable new patient segment for BioMarin, complementing its existing PKU portfolio and bolstering revenue diversification. The company’s parallel pursuit of EMA endorsement signals intent to capture the European market, while its recent $270 million acquisition of Inozyme Pharma underscores a strategic push into broader metabolic and rare‑disease spaces. Collectively, these moves position BioMarin to capitalize on growing demand for innovative, patient‑centric solutions in the rare‑disease arena.